Biomarkers /
MYH9
Overview
Myosin, heavy chain 9, non-muscle (MYH9) is a gene that encodes a protein that functions as a conventional non-muscle myosin that participates in cytokinesis, cell motility, and maintenance of cell shape. Fusions, missense mutations, nonsense mutations, silent mutations, frameshift deletions, and in-frame deletions and insertions are observed in cancers such as endometrial cancer, intestinal cancer, and stomach cancer.
MYH9 is altered in 0.46% of all cancers with breast invasive ductal carcinoma, endometrial endometrioid adenocarcinoma, lung adenocarcinoma, mixed lobular and ductal breast carcinoma, and conventional glioblastoma multiforme having the greatest prevalence of alterations [3].
The most common alterations in MYH9 are MYH9-ALK Fusion (0.08%), MYH9 Amplification (0.37%), MYH9 Fusion (0.01%), MYH9-NTRK3 Fusion (0.03%), and MYH9 N470S (0.17%) [3].
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.